Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-341, D956
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 51
- Registration Number
- NCT06281132
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Test drugDrug: CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06204107
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: D064 and D702, QDDrug: D064 and Placebo of D702, QDDrug: Placebo of D064 and D702, QD
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 235
- Registration Number
- NCT06121518
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Seongdong-gu, Korea, Republic of
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT06110923
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)
Phase 1
Completed
- Conditions
- HypertensionDyslipidemias
- Interventions
- Drug: CKD-828, D097, D337
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 63
- Registration Number
- NCT06112678
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)
Phase 1
Completed
- Conditions
- Dyslipidemias
- Interventions
- Drug: CKD-391(2)Drug: CKD-331, D337
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 66
- Registration Number
- NCT06088017
- Locations
- 🇰🇷
Bumin hopspital, Seoul, Seoul, Gangseo-gu, Korea, Republic of
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Phase 4
Recruiting
- Conditions
- Kidney Transplant
- Interventions
- Drug: Myreptic-N Tablet
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 158
- Registration Number
- NCT06044493
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study to Evaluate the Safety and Pharmacokinetics of CKD-379
Phase 1
Active, not recruiting
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: D759+D745+D029+D150
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05952219
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: D064, D702, placebo of D660Drug: D660, placebo of D064, placebo of D702
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 346
- Registration Number
- NCT05931224
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Bundang-gu, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150
Phase 1
Completed
- Conditions
- Diabetes type2
- Interventions
- Drug: D745, D759, D150
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT05928637
- Locations
- 🇰🇷
Catholic Hospital, Seoul, Seoul, Korea, Republic of